

SCIENTIFIC BOARD

Atto BILLIO (*Bolzano-IT*) - Dominik WOLF (*Innsbruck-AT*)

FACULTY

Giuseppe AVVISATI (*Rome-IT*)
Renato BASSAN (*Mestre-IT*)
Roberto CAIROLI (*Milan-IT*)
Anna CANDONI (*Udine-IT*)
Sabina CHIARETTI (*Rome-IT*)
Renato FANIN (*Udine-IT*)
Felicetto FERRARA (*Naples-IT*)
Filippo GHERLINZONI (*Treviso-IT*)
Alexander HAUSWIRTH (*Vienna-AT*)
Dieter HOELZER (*Frankfurt-DE*)
Philipp JOST (*Munich-DE*)
Mauro KRAMPERA (*Verona-IT*)
Nicolaus KRÖGER (*Hamburg-DE*)
Georg MANN (*Vienna-AT*)
Giovanni MARTINELLI (*Meldola-IT*)
Federico MOSNA (*Bolzano-IT*)
Peter PASCHKA (*Ulm-DE*)
Alessandro RAMBALDI (*Bergamo-IT*)
Giuseppe ROSSI (*Brescia-IT*)
Giampietro SEMENZATO (*Padua-IT*)
Max TOPP (*Würzburg-DE*)
Adriano VENDITTI (*Rome-IT*)

VENUE

Sparkasse Academy
Cassa di Risparmio
Via Cassa di Risparmio, 16
39100 Bolzano

CME CREDITS

8 Italian credits for Continuing Medical Education (CME) for Physician.

REGISTRATION

Congress registration is required and free of charge.
On-line registration at www.organizing.it
(while seats last).

CME PROVIDER AND ORGANIZING SECRETARIAT ORGANIZING^{SRL}

Via Santuario, 41
35031 ABANO TERME - Padova
Tel. 049 8025202 - 049 8036743
E-mail: info@organizing.it



CON LA SPONSORIZZAZIONE
NON CONDIZIONANTE DI

janssen Oncology

PHARMACEUTICAL COMPANIES OF *Johnson & Johnson*



First Alpine Region Hematology in focus meeting

Topic: Acute Leukemia

BOLZANO 14-15 November 2019

**SPARKASSE ACADEMY
CASSA DI RISPARMIO**

Scientific Board
Atto Billio (*Bolzano*) - Dominik Wolf (*Innsbruck*)

First Alpine Region Hematology in focus meeting

Topic: Acute Leukemia

PROGRAM



Thursday, 14 November 2019

13.30-14.00 Registration

14.00-14.15 Introduction. *A. Billio, D. Wolf*

14.15-14.30 Greetings from Authorities

FROM BENCH TO THE CLINIC

Moderators: *R. Cairoli, M. Krampera*

14.30-14.55 How do genetics of AML patients influence prognosis, treatment strategies and follow-up today and tomorrow? *P. Paschka*

14.55-15.20 Targeted therapy in AML: what do the guidelines tell us? *D. Wolf*

15.20-15.45 Targeted therapy in AML: what does the science tell us? *G. Martinelli*

15.45-16.10 Arsenic and old lace: biology and treatment of APL. *G. Avvisati*

16.10-16.30 Coffee break

THE GOLDEN AGE

Moderators: *G. Rossi, P. Paschka*

16.30-16.55 Between Scilla and Cariddi: intensive therapy versus hypomethylating agents for the treatment of older patients. *F. Ferrara*

16.55-17.10 Targeting BCL2 in hematology: from CLL to AML to stem cells. *P. Jost*

17.10-17.35 The Allo affair beyond 65 years: who benefits? *N. Kröger*

17.35-17.50 Elderly core-binding factor AML: a real life snapshot. *F. Mosna*

THE DARK ROOM

Moderator: *G. Martinelli*

17.50-18.15 Saving private Ryan: the case of refractory AML. *A. Rambaldi*

18.15-18.40 Diagnosis, prognosis and therapeutic approach in secondary AML. *A. Venditti*



Friday, 15 November 2019

08.15-08.30 Registration

TREATMENT STRATEGIES IN ALL: FIRST LINE ISSUES

Moderators: *G. Semenzato, R. Bassan*

08.30-08.45 First line therapy of adults ALL: the Italian Protocol. *R. Bassan*

08.45-09.00 Evolvement of first line therapy in adult ALL: the German Protocol. *D. Hoelzer*

09.00-09.20 Forever young: time for pure pediatric protocols? *G. Mann*

09.20-09.40 Discussion

TREATMENT STRATEGIES IN ALL: DRUGS ISSUES

Moderators: *F. Gherlinzoni, D. Hoelzer*

09.40-10.05 Asparaginases: a users guide. *A. Candoni*

10.05-10.30 Treatment of adult ALL relapse. *A. Hauswirth*

10.30-10.50 T cell engaging immunotherapy for ALL. *M. Topp*

10.50-11.15 Coffee break

ALL: BEYOND THE STANDARDS

Moderator: *R. Fanin*

11.15-11.40 Philadelphia-like ALL: diagnosis and treatment. *S. Chiaretti*

11.40-12.05 Therapy of Ph positive ALL. *S. Chiaretti*

12.05-13.00 Final remarks - CME Test

13.00-14.00 Light lunch